DaVita HealthCare Partners (NYSE:DVA) had its price target boosted by J P Morgan Chase & Co from $4.90 to $84.00 in a research report issued on Thursday. The firm currently has a “strong-buy” rating on the stock. J P Morgan Chase & Co’s price target points to a potential upside of 21.39% from the stock’s current price.

DVA has been the subject of a number of other research reports. SunTrust Banks increased their price target on DaVita HealthCare Partners to $70.00 and gave the company a “hold” rating in a report on Thursday. KeyCorp reissued a “hold” rating on shares of DaVita HealthCare Partners in a report on Wednesday. Raymond James Financial raised DaVita HealthCare Partners from an “outperform” rating to a “strong-buy” rating in a report on Thursday. Robert W. Baird reissued a “hold” rating and issued a $63.00 price target on shares of DaVita HealthCare Partners in a report on Friday, November 10th. Finally, Royal Bank Of Canada reduced their price target on DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $67.86.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded up $8.27 during midday trading on Thursday, hitting $69.20. The stock had a trading volume of 9,753,800 shares, compared to its average volume of 1,639,776. DaVita HealthCare Partners has a 52 week low of $52.51 and a 52 week high of $70.16. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. The stock has a market capitalization of $11,529.89, a P/E ratio of 17.41, a price-to-earnings-growth ratio of 12.28 and a beta of 0.97.

DaVita HealthCare Partners (NYSE:DVA) last issued its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The company had revenue of $3.92 billion during the quarter, compared to analysts’ expectations of $3.91 billion. During the same period in the previous year, the company earned $0.95 EPS. DaVita HealthCare Partners’s quarterly revenue was up 5.2% on a year-over-year basis. sell-side analysts expect that DaVita HealthCare Partners will post 3.42 earnings per share for the current fiscal year.

DaVita HealthCare Partners announced that its Board of Directors has initiated a stock buyback plan on Tuesday, October 10th that permits the company to buyback $1.50 billion in outstanding shares. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in DaVita HealthCare Partners by 4.4% during the third quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock valued at $19,073,000 after buying an additional 13,471 shares in the last quarter. Riverhead Capital Management LLC raised its stake in DaVita HealthCare Partners by 10.6% during the second quarter. Riverhead Capital Management LLC now owns 112,506 shares of the company’s stock valued at $7,286,000 after buying an additional 10,775 shares in the last quarter. Founders Capital Management LLC raised its stake in DaVita HealthCare Partners by 2.3% during the third quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock valued at $5,698,000 after buying an additional 2,115 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its stake in DaVita HealthCare Partners by 1,987.3% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock valued at $2,448,000 after buying an additional 39,746 shares in the last quarter. Finally, Speece Thorson Capital Group Inc. raised its stake in DaVita HealthCare Partners by 14.5% during the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after buying an additional 40,667 shares in the last quarter. Hedge funds and other institutional investors own 85.32% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/davita-healthcare-partners-dva-pt-raised-to-84-00-at-j-p-morgan-chase-co.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.